Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s EBIT?
- Denali Therapeutics Inc. (DNLI) reported EBIT of -$130.54M in Q2 2026.
- How has Denali Therapeutics Inc.'s EBIT changed year-over-year?
- Denali Therapeutics Inc.'s EBIT increased by 3.3% year-over-year, from -$134.96M to -$130.54M.
- What is the long-term trend for Denali Therapeutics Inc.'s EBIT?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s EBIT has grown at a 17.1% compound annual growth rate (CAGR), from -$295.75M to -$555.34M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Denali Therapeutics Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude